4-(4-氟苯基)丁酸 | 589-06-0

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(4-氟苯基)丁酸
• 中文别名: 当归提取液；4-(4-氟-苯基)-丁酸
• 英文名称: 4-(4-fluorophenyl)butanoic acid
• 英文别名: 4-(4-fluorophenyl)butyric acid；β-(p-fluorobenzyl)propionic acid
• CAS: 589-06-0
• 化学式: C₁₀H₁₁FO₂
• 分子量: 182.195
• InChiKey: XVQYBBYOYJXQBF-UHFFFAOYSA-N

物化性质

• 熔点：
  45 °C
• 沸点：
  161-164 °C(Press: 4 Torr)
• 密度：
  1.182±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi,C
• 海关编码：
  2916399090
• 安全说明：
  S24/25
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Name:	4-(4-Fluorophenyl)butyric acid Material Safety Data Sheet
Synonym:	None Known.
CAS:	589-06-0

Section 1 - Chemical Product MSDS Name: 4-(4-Fluorophenyl)butyric acid Material Safety Data Sheet
Synonym: None Known.

---

SECTION 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
589-06-0	4-(4-Fluorophenyl)butyric acid	ca. 100	209-631-8

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

SECTION 3 - HAZARDS IDENTIFICATION EMERGENCY OVERVIEW The toxicological properties of this material have not been fully investigated. Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated. May be harmful if inhaled.
Chronic:
No information found.

---

SECTION 4 - FIRST AID MEASURES
Eyes:
In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. Get medical aid.
Skin:
In case of contact, flush skin with plenty of water. Remove contaminated clothing and shoes. Get medical aid if irritation develops and persists. Wash clothing before reuse.
Ingestion:
If swallowed, do not induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious person. Get medical aid.
Inhalation:
If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

SECTION 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

SECTION 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions. Provide ventilation.

---

SECTION 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

SECTION 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low. Exposure Limits CAS# 589-06-0: Personal Protective Equipment
Eyes:
Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

SECTION 9 - PHYSICAL AND CHEMICAL PROPERTIES
Physical State: Crystalline powder
Color: off-white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 38 - 40 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water: insoluble
Specific Gravity/Density:
Molecular Formula: C10H11FO2
Molecular Weight: 210.18

---

SECTION 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not currently available.
Conditions to Avoid:
Dust generation.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide, hydrogen fluoride gas.
Hazardous Polymerization: Has not been reported

---

SECTION 11 - TOXICOLOGICAL INFORMATION RTECS#: CAS# 589-06-0 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-(4-Fluorophenyl)butyric acid - Not listed by ACGIH, IARC, or NTP.

---

SECTION 12 - ECOLOGICAL INFORMATION

---

SECTION 13 - DISPOSAL CONSIDERATIONS Dispose of in a manner consistent with federal, state, and local regulations.

---

SECTION 14 - TRANSPORT INFORMATION IATA Not regulated as a hazardous material. IMO Not regulated as a hazardous material. RID/ADR Not regulated as a hazardous material.

---

SECTION 15 - REGULATORY INFORMATION European/International Regulations European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases: S 24/25 Avoid contact with skin and eyes. WGK (Water Danger/Protection) CAS# 589-06-0: No information available. Canada None of the chemicals in this product are listed on the DSL/NDSL list. CAS# 589-06-0 is not listed on Canada's Ingredient Disclosure List. US FEDERAL TSCA CAS# 589-06-0 is not listed on the TSCA inventory. It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
MSDS Creation Date: 4/03/2003 Revision #1 Date: 7/25/2003 The information above is believed to be accurate and represents the best information currently available to us. However, we make no warranty of merchantability or any other warranty, express or implied, with respect to such information, and we assume no liability resulting from its use. Users should make their own investigations to determine the suitability of the information for their particular purposes. In no way shall the company be liable for any claims, losses, or damages of any third party or for lost profits or any special, indirect, incidental, consequential or exemplary damages, howsoever arising, even if the company has been advised of the possibility of such damages.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(4-氟苯基)丁酸 在 磷酸酐 、 磷酸 作用下， 反应 1.5h， 生成 7-氟-2-萘酮
  参考文献：
  名称：

  EP1403256

  摘要：

  公开号：
• 作为产物：
  描述：

  氟苯 在 aluminum (III) chloride 、 hydrazine hydrate 、 potassium hydroxide 作用下， 以 乙二醇 为溶剂， 反应 10.5h， 生成 4-(4-氟苯基)丁酸
  参考文献：
  名称：

  碘和光氧化还原协同催化直接氧化羧酸的内酯化†

  摘要：

  描述了一种通过直接将苄基CH键转换为CO键从羧酸形成γ-和δ-内酯的新方法。该反应由可见光方便地诱导，并且依赖于分子碘和有机染料的组合的温和协同催化。

  DOI：

  10.1039/c8cc08594c

文献信息

• [EN] NOVEL AGENTS TARGETING CYP51<br/>[FR] NOUVEAUX AGENTS CIBLANT CYP51
  申请人：SCRIPPS RESEARCH INST

  公开号：WO2015048306A1

  公开（公告）日：2015-04-02

  The invention provides inhibitors of a sterol C14-demethylase, a new series of 4- aminopyridyl-based lead inhibitors targeting Trypanosoma cruzi CYP51 (TcCYP51) developed using structure-based drug design as well as structure -property relationship (SPR) analyses. The screening hit starting point, LP 10 (KD < 42 nM; EC50 of 0.65 μΜ), has been optimized to give the potential leads that have low nanomolar binding affinity to TcCYP51 and significant activity against T. cruzi amastigotes cultured in human myoblasts. Many of the optimized compounds have improved microsome stability, and most are selective against the T. cruzi CYP51 relative to human CYPs 1A2, 2D6 and 3A4 (<50% inhibition at 1 μΜ). A rationale for the improvement of microsome stability and selectivity of inhibitors against human metabolic CYP enzymes is presented. In addition, the binding mode of several compounds of the invention with the T. brucei CYP51 (TbCYP51) ortholog has been characterized by x-ray structure analysis. Orally active compounds and their cyclodextrin complexes have been shown to be effective against Chagas-infected mice.

  该发明提供了一种甾醇C14-去甲基酶的抑制剂，这是一种新系列基于4-氨基吡啶的首选抑制剂，通过基于结构的药物设计以及结构-性质关系（SPR）分析来瞄准Trypanosoma cruzi CYP51（TcCYP51）而开发的。筛选起始点LP 10（KD < 42 nM；EC50为0.65 μΜ）已经经过优化，产生了具有低纳摩尔级别结合亲和力和对在人类肌细胞培养的T. cruzi游离体的显著活性的潜在首选抑制剂。许多经过优化的化合物具有改善的微粒体稳定性，大多数相对于人类CYPs 1A2、2D6和3A4对T. cruzi CYP51具有选择性（在1 μΜ下<50%的抑制）。提出了改善微粒体稳定性和抑制剂对人类代谢CYP酶的选择性的理由。此外，通过X射线结构分析表征了该发明的几种化合物与T. brucei CYP51（TbCYP51）同源物的结合方式。口服活性化合物及其环糊精复合物已被证明对克氏病感染的小鼠有效。
• Ligand‐Controlled Regiodivergence in Nickel‐Catalyzed Hydroarylation and Hydroalkenylation of Alkenyl Carboxylic Acids**
  作者：Zi‐Qi Li、Yue Fu、Ruohan Deng、Van T. Tran、Yang Gao、Peng Liu、Keary M. Engle

  DOI：10.1002/anie.202010840

  日期：2020.12.14

  the ligand environment around the metal center dictates the regiochemical outcome. Markovnikov hydrofunctionalization products are obtained under mild ligand‐free conditions, with up to 99 % yield and >20:1 selectivity. Alternatively, anti‐Markovnikov products can be accessed with a novel 4,4‐disubstituted Pyrox ligand in excellent yield and >20:1 selectivity. Both electronic and steric effects on the

  据报道，镍催化的未活化链烯基羧酸的区域发散性氢芳基化和氢烯基化，从而金属中心周围的配体环境决定了区域化学结果。Markovnikov加氢官能化产物是在无配体的温和条件下获得的，产率高达99％，选择性> 20：1。另外，可以使用新型的4,4-二取代的Pyrox配体获得抗Markovnikov产物，并具有优异的收率和> 20：1的选择性。对配体的电子和空间效应都有助于高产率和选择性。机理研究表明，最佳配体引起的营业额限制和选择性决定步骤发生了变化。DFT计算表明，在反马尔科夫尼科夫途径中，
• Synthesis of Novel Pterocarpen Analogues <i>via</i> [3 + 2] Coupling‐Elimination Cascade of α,α‐Dicyanoolefins with Quinone Monoimines
  作者：Hui Chen、Sihan Zhao、Shaobing Cheng、Xingjie Dai、Xiaoying Xu、Weicheng Yuan、Xiaomei Zhang

  DOI：10.1002/jhet.3543

  日期：2019.5

  By employing triethylamine as a catalyst, [3 + 2] coupling‐elimination cascade of α,α‐dicyanoolefins with quinone monoimines was realized. The reactions afforded various novel pterocarpen analogues with generally moderate yields (up to 75%). In addition, a plausible reaction mechanism was proposed.

  以三乙胺为催化剂，实现了α，α-二氰基烯烃与醌单亚胺的[3 + 2]偶合消除级联反应。反应提供了各种新的翼果木类似物，具有通常中等的收率（高达75％）。另外，提出了合理的反应机理。
• [EN] NOVEL RADIOLABELLED CXCR4-TARGETING COMPOUNDS FOR DIAGNOSIS AND THERAPY<br/>[FR] NOUVEAUX COMPOSÉS RADIOMARQUÉS DIAGNOSTIQUES ET THÉRAPEUTIQUES CIBLANT CXCR4
  申请人：PROVINCIAL HEALTH SERVICES AUTHORITY

  公开号：WO2020210919A1

  公开（公告）日：2020-10-22

  This application relates to compounds of Formula (I): [targeting peptide]-N(R1)-X1(R2)L1-[linker]-RX n1 (I). The targeting peptide is cyclo[L-Phe-L-Tyr-L-Lys(iPr)-D-Arg-L-2-Nal-Gly-D-Glu]-L-Lys(iPr). R1 is H or methyl. X1 is an optionally substituted C1-C15 hydrocarbon optionally comprising heteroatoms. R2 is C(O)OH or C(O)NH2. L1 is a linkage (thiolether, amide, maleimide-thiol, triazole). The linker has a net negative charge at physiological pH and is a linear or branched chain of 1-10 units of X2L2 and/or X2(L2)2, wherein: each X2 is, independently, an optionally substituted C1-C15 hydrocarbon optionally comprising heteroatoms; and each L2 is a linkage. The linker optionally further comprises an albumin binder bonded to an L2. Each RX is a radiolabelling group linked through a separate L2, selected from: a metal chelator; a prosthetic group containing trifluoroborate (BF3); or a prosthetic group containing a silicon-fluorine-acceptor moiety. The compounds may be useful for imaging CXCR4-expressing tissues or for treating CXCR4-associated diseases or conditions (e.g. cancer).

  这个应用涉及到Formula (I)的化合物：[靶向肽]-N(R1)-X1(R2)L1-[连接物]-RX n1 (I)。靶向肽是cyclo[L-Phe-L-Tyr-L-Lys(iPr)-D-Arg-L-2-Nal-Gly-D-Glu]-L-Lys(iPr)。R1是H或甲基。X1是一个可选择地取代的含有杂原子的C1-C15烃。R2是C(O)OH或C(O)NH2。L1是一个连接物（硫醚、酰胺、马来酰亚胺-硫醇、三唑）。连接物在生理pH下具有净负电荷，是由1-10个X2L2和/或X2(L2)2的线性或支链构成，其中：每个X2独立地是一个可选择地取代的含有杂原子的C1-C15烃；每个L2是一个连接物。连接物可选择地进一步包括与L2结合的白蛋白结合剂。每个RX是通过单独的L2连接的放射标记基团，选自：金属螯合剂；含三氟硼酸盐（BF3）的假体基团；或含硅-氟受体基团的假体基团。这些化合物可能对于成像CXCR4表达组织或治疗与CXCR4相关的疾病或症状（如癌症）有用。
• Synthesis and antiallergic activity of 2-hydroxy-3-nitro-1,4-naphthoquinones
  作者：Derek R. Buckle、Barrie C. C. Cantello、Harry Smith、Raymond J. Smith、Barbara A. Spicer

  DOI：10.1021/jm00218a014

  日期：1977.8

  have highest potency with alkyl substitution at both C-6 and C-7. The most potent compounds were 7c and 7e which produced a 50% inhibition in the rat PCA test at doses of about 10 micrometerM/kg following subcutaneous administration and showed activity after oral administration. Related 4-hydroxy-3-nitro-2(1H)-naphthalenones had no effect on rat PCA in doses up to 500 micrometerM/kg.

  新型2-羟基-3-硝基-1,4-萘醌的选择被证明是大鼠被动皮肤过敏反应（PCA）的有效抑制剂，并且在C-6和C-7处具有最高的烷基取代效力。最有效的化合物是7c和7e，它们在大鼠PCA测试中以约10微米M / kg的剂量在皮下给药后产生50％的抑制作用，并在口服后显示出活性。相关的4-羟基-3-硝基-2（1H）-萘烯酮对大鼠PCA的影响最大为500 microM / kg。